EGFL7 and hepatocellular carcinoma: Recent studies revealed that EGFL7 expressed and correlated with clinical features in several tumors, suggesting its potential use as a therapeutic target for cancers including breast cancer (7), epithelial ovarian cancer (8), hepatocellular carcinoma (9), colorectal cancer (10), acute myeloid leukemia (11), and malignant glioma (12, 13).